

The 2023 Digital Learning Journey on Growth Disorders

LIVE WEBINAR
Challenges and developments in growth
and metabolic disorders

5 October 2023
From 13:00 to 15.30 CEST

Final Programme

For website page
CLICK HERE



Endorsed by

OVERVIEW

Children born small for gestational age (SGA) can present growth disorders (GD) after birth, although generally they fill the developmental gap after 2 years. In some cases, no catch-up is obtained, so that a careful management must be offered to SGA children in order to achieve a normal height. The most common cause of GD is growth hormone deficiency (GHD). GHD can be caused by many different conditions and may be difficult to identify them properly. Among the challenges in the diagnosis of GHD there is the discrimination between GHD itself and constitutional delay of growth and puberty (CDGP)

LEARNING OBJECTIVES:

- Recognize and diagnose growth hormone deficiency
- Describe the clinical scenarios associated with growth hormone deficiency
- Address the challenges of transitioning from paediatric to adult care of patients with growth hormone deficiency
- Outline other clinical conditions and co-morbidities that can impact growth hormone deficiency and its management (e.g. obesity)

TARGET AUDIENCE:

Paediatricians, endocrinologists, paediatric endocrinologists, general practitioners and nurses

LANGUAGE

English with simultaneous translation into Spanish

For registration
CLICK HERE



REGISTRATION IS FREE
OF CHARGE

CONTINUING MEDICAL EDUCATION

The “**Challenges and developments in growth and metabolic disorders**” Rome, Italy, 05/10/2023- 05/10/2023” has been accredited by the **European Accreditation Council for Continuing Medical Education (EACCME®)** with **2 European CME credits (ECMEC®s)**. Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME® credit to AMA credit can be found at www.ama-assn.org/education/earn-credit-participation-international-activities.

Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.



CME PROVIDER

Scientific Seminars International Foundation

Program Manager: Annamaria Nesticò

annamaria.nesticò@scientificseminars.com


MEDICAL ADVISOR

Tommaso Todisco

Endocrinology Unit

Bambino Gesù Children's Hospital IRCCS

Rome, Italy



FACULTY

Henry Anhalt

Pediatric Diabetes and Endocrinology
Hackensack (NJ), USA

Marco Cappa

Research Area for Innovative
Therapies for Endocrinopathies
Bambino Gesù Children's Hospital
IRCCS
Rome, Italy

Mehul Dattani

Genetics and Genomic
Medicine Programme
UCL Great Ormond Street Institute
of Child Health
London, UK

Alan D. Rogol

Division of Endocrinology
University of Virginia
Charlottesville (VA), USA

Martin O. Savage








William Harvey Research Institute
Barts and the London School of
Medicine & Dentistry
Queen Mary, University of London
London, UK

SCIENTIFIC PROGRAM

CHALLENGES AND DEVELOPMENTS IN GROWTH AND METABOLIC DISORDERS

THURSDAY, 5 OCTOBER 2023

From 13:00 to 15:30 CEST

13.00		Welcome and Introduction H. Anhalt (USA) - M.O. Savage (UK)
13.05		L1 Clinical suspicion of GH deficiency (GHD): The role of the GH stimulation test in diagnosis of GHD M. Cappa (Italy)
13.35		L2 SGA children: how to provide adequate endocrine care to growth disorder high risk patients Standardisation issue within GH practice M. Dattani (UK)
14.05		L3 Constitutional delay of growth and puberty: how to identify false GHD patients A. Rogol (USA)
14.35		L4 GH Deficiency in transition age and GH Deficiency in adults M. O. Savage (UK)
15.05		Q&A
15.25		Concluding Remarks H. Anhalt (USA) - M.O. Savage (UK)
15.30		End of the live webinar

LEGEND

 Lecture  Q&A  Concluding Remarks

FACULTY DISCLOSURES

Scientific Seminars International Foundation adheres to guidelines of the European Accreditation Council for Continuing Medical Education (EACCME®) and all other professional organizations, as applicable, which state that programs awarding continuing education credits must be balanced, independent, objective and scientifically rigorous. Investigative and other uses for pharmaceutical agents, medical devices and other products (other than those uses indicated in approved product labelling/package insert for the product) may be presented in the program (which may reflect clinical experience, the professional literature or other clinical sources known to the presenter). We ask all presenters to provide participants with information about relationships with pharmaceutical or medical equipment companies that may have relevance to their lectures. This policy is not intended to exclude faculty who have relationships with such companies; it is only intended to inform participants of any potential conflicts so that participants may form their own judgements, based on full disclosure of the facts. Further, all opinions and recommendations presented during the program and all program-related materials neither imply an endorsement nor a recommendation on the part of Scientific Seminars International Foundation. All presentations represent solely the independent views of the presenters/authors.

The following faculty provided information regarding significant commercial relationships and/or discussions of investigational or non-EMEA/FDA approved (off-label) uses of drugs:

Henry Anhalt	Declared no potential conflict of interest
Marco Cappa	Declared receipt of grants and contracts from Novo Nordisk, Merck Serono and honoraria or consultation fees from Rhythm, Pfizer, Sandoz, Amryt
Mehul Dattani	Declared receipt of honoraria or consultation fees from Pfizer, Novo Nordisk, Sandoz, Ferring, to be a member of Pfizer advisory board and to participate in Novo Nordisk and Sandoz sponsored speakers' bureau
Alan D. Rogol	Declared receipt of honoraria or consultation fees from Acerus Pharma, Ascendis Pharma, BioMarin Pharmaceuticals, Lumos Pharma, Pfizer, Tolmar Pharmaceuticals
Martin O. Savage	Declared receipt of grants and contracts from Pfizer, receipt of honoraria or consultation fees from Merck Healthcare KGaA Darmstadt, Ipsen, Visen, Springer-Nature IME, Sandoz UK and Global and to participate in Pfizer Advisory Board

CHAIRMAN

Martin O. Savage



Martin Savage is Emeritus Professor of Paediatric Endocrinology at William Harvey Research Institute, Barts and the London School of Medicine & Dentistry, Queen Mary, University of London. He was head of the Paediatric Endocrine Unit at Barts and the London School of Medicine from 1982 to 2007. He has interests in growth disorders, specifically those with abnormalities in the GH-IGF-1 axis and in phenotype-genotype relationships of GH-IGF-1 axis defects, notably GH resistance. He published the first human case of an IGF-1 gene defect in the *New England Journal of Medicine* in 1996. His other interests are Cushing's syndrome and growth in chronic inflammatory diseases. He was General Secretary of the European Society for Paediatric Endocrinology (ESPE) from 1997 to 2004. He has lectured in 61 countries and has published 472 original articles, reviews, textbook chapters and books. In 2007, he was awarded the ESPE Andrea Prader Prize for contributions to paediatric endocrinology and in 2018 he received a Visionary Award from the American Human Growth Foundation. In 2022, he received a Research Excellence Award from the Dr Sulaiman Al Habib Medical Journal in Riyadh, and the British Society of Paediatric Endocrinology & Diabetes James M. Tanner Lifetime Achievement Award. He continues to lecture nationally and internationally.

CO-CHAIRMAN

Henry Anhalt



Dr. Henry Anhalt is a board-certified pediatric endocrinologist who is recognized globally as a key opinion leader in diabetes and endocrinology clinical care, advocacy and research. Currently, Dr. Anhalt is responsible for the strategic, medical and scientific leadership for embecta, which includes, clinical development and evidence generation, medical affairs activities, providing subject matter expertise for business development and oversight of the safety and efficacy of the company's portfolio of diabetes products. Dr. Anhalt serves as Vice President, Chief Medical Officer and Global Head of Clinical Medical and Scientific Affairs for embecta. A physician-scientist whose career spans academia, industry, non-profit and biotech, Dr. Anhalt has held several leadership positions of increasing responsibilities including most recently Executive Director, Medical Affairs, for Provention Bio, a clinical-stage biopharmaceutical company developing novel therapeutics aimed at intercepting and preventing Type 1 diabetes. As the Vice President, Medical Affairs, for Science 37, a decentralized clinical research organization, he was the lead physician for the diabetes, metabolism and endocrinology research unit responsible to develop protocols and novel endpoints in addition to serving as principal investigator. Prior to that, he served as Chief Medical Officer of the T1D Exchange, a non-profit funded by the Helmsley Charitable Trust that established the first registry for people with T1 diabetes with over 28,000 patients and a clinical trial network of over 90 clinical trial sites. Under his leadership the first multicenter quality improvement program for T1D was established leading to best practices and improved outcomes in care. Prior to that he served as senior medical director and interim head of North America Medical Affairs at Sanofi responsible to bring a novel basal insulin through regulatory approval and launch in north America. His first opportunity in Industry was at Animas, a Johnson & Johnson Company, whereas Chief Medical Officer, he served on the management board, and as Medical Director in charge of the Artificial Pancreas Project, a partnership between Animas and JDRF to develop and commercialize the first closed loop automated insulin delivery device. Dr. Anhalt is frequently invited to speak to national and international audiences, and is often quoted in national media including Reuters, USA Today, Business Insider and WebMD. He has also appeared on CNN, CNBC and NPR. He has served on the editorial board of Endocrine News, and has authored over 40 original manuscripts, dozens of abstracts, consensus statements, textbook chapters and clinical reviews. He has been a longtime member-volunteer of the Endocrine Society, the largest global organization representing endocrinologists and most recently sat on it's board of directors. Dr. Anhalt is a board member of Camp Nejedá, which is a residential summer camp that serves over 500 children with diabetes, as well as Insulin for Life USA, a non-profit that provides insulin and diabetes supplies globally for those in need. Known as a champion of technology use in diabetes he continues to see patients in his general pediatric endocrinology practice.

FACULTY



Marco Cappa

Prof. Marco Cappa is Professor in Pediatrics at "Scuola di Pediatria" University of Tor Vergata, Genetics at Catholic University of Rome, and in Endocrinology at University "La Sapienza" in Rome. In 2013 Licensed as full Professor in Pediatrics. From 2011 to 2013 he served as President of the Italian Society For Pediatric Endocrinology. Prof. Cappa's specialties include endocrinology, pediatrics, and sports medicine. His scientific areas of interests include neuroendocrinology and genetics. He is component of CEFT NADO Italia (WADA).

His specialties include: Growth mechanism and Pubertal development (Hypothalamic Pituitary Gonadal axis), Adrenoleukodystrophy, Generalized and partial Lipodystrophy, CAH, Genetic obesity comprising Prader-Willi syndrome.

He is a widely published author in the most important international journals. His h-index is 46 and he published more than 350 peer review papers.

FACULTY

Mehul Dattani



Mehul Dattani is Professor of Paediatric Endocrinology based at the University College London (UCL) Great Ormond Street, Institute of Child Health, and Specialty Lead in Endocrinology at Great Ormond Street Hospital for Children (GOSH). He has an active clinical practice in paediatric and adolescent Endocrinology at GOSH and University College London Hospitals (UCLH). He completed a 3-year term as Chair of the British Society for Paediatric Endocrinology and Diabetes, followed by a 7 year term as Chair of the Programme Organizing Committee and member of the Council of the European Society for Paediatric Endocrinology (ESPE). He is the Convenor/Host of the European Society for Paediatric Endocrinology for 2024, and hosted the ESPE 2021 Online Annual Meeting. He has also served as co-Chair of the Pituitary Main Thematic Group of the ENDO-ERN initiative until December 2020.

Professor Dattani has established a laboratory group investigating the molecular basis of hypothalamo-pituitary disease at UCL. He has identified novel genes implicated in hypothalamo-pituitary development in patients with congenital hypopituitarism, and has worked on understanding the molecular basis of a paediatric brain tumour called adamantinomatous craniopharyngioma. He has more than 250 publications including original articles and scholarly reviews in a number of high impact journals, as well as numerous book chapters. He sits on numerous advisory boards and editorial boards of journals. He has previously received the ESPE Henning Andersen awards (on 2 occasions), RCPCH Donald Paterson Award, the Kalaitzoglou Prize from The Hellenic Society of Pediatric and Adolescent Endocrinology, the 2022 Visionary award from the Human Growth Foundation, and the 2022 ESPE Research Award for his scientific work. He has co-authored 3 textbooks to date, including the 7th Edition of Brook's Clinical Paediatric Endocrinology.

FACULTY

Alan D. Rogol



Alan D. Rogol, MD, Ph.D is Professor Emeritus (Pediatrics and Pharmacology) at the University of Virginia. He received an undergraduate degree in chemistry from the Massachusetts Institute of Technology (MIT), and doctorates in medicine and physiology (Endocrinology) from Duke University. He completed a residency in pediatrics at the Johns Hopkins Hospital. Following a fellowship in endocrinology at the National Institutes of Health (NIH), he moved to the University of Virginia (UVA), ultimately serving as Professor of Pediatrics and Pharmacology and Chief of the Division of Endocrinology.

Since 1999 Dr Rogol has led an eclectic existence, first in the pharmaceutical industry and then as a safety monitor, but continuing to practice pediatric endocrinology and to teach at UVA and Riley Hospital for Children in Indianapolis, IN (2009-2013).

Dr Rogol has been a member and Chief of the American Board of Pediatrics, sub-board in endocrinology; Secretary of the Lawson Wilkins Pediatric Endocrine Society (now known as the Pediatric Endocrine Society), and has served as Vice-President of The Endocrine Society. He is a Fellow of the American Academy of Pediatrics and the American College of Sports Medicine and a member of the American Pediatric Society.

He has been the recipient of the Human Growth Foundation Lifetime Award, the Judson J. Van Wyk Prize for Career Achievement in Pediatric Endocrinology from the Pediatric Endocrine Society and the Lifetime Achievement Award in Pediatric Science from the Child Health Research Center from the University of Virginia.

His interests in endocrinology have included growth and puberty and lately the endocrinology of sport and exercise. Dr Rogol has published more than 600 scientific articles, is a member of several editorial boards, and was the co-editor of The Encyclopaedia of Sports Medicine: An International Olympic Commission (IOC) Medical Commission Publication (vol 11): The Endocrine System in Sports and Exercise.

All Scientific Seminars International Foundation programs are organized solely to promote the exchange and dissemination of scientific and medical information. No forms of promotional activities are permitted. There may be presentations discussing investigational uses of various products. These views are the responsibility of the named speakers, and do not represent an endorsement or recommendation on the part of Scientific Seminars International Foundation. This independent educational program is made possible thanks to an educational grant received from Merck Healthcare KGaA, Darmstadt, Germany.

**For registration
CLICK HERE**



REGISTRATION IS FREE
OF CHARGE



Scientific Seminars International Foundation

Via di Porta Pinciana, 6 - 00187 Roma
www.scientificseminars.com

